NG2-73 - A Novel Agent For The Treatment of Insomnia
Key Data:
Drug (Brand/Generic)
NG2-73
Company/Licensee
Neurogen
Therapy Class
GABA partial agonist
Product Description
A selective, partial GABA alpha-3 agonist
Current Indication
Treatment of insomnia
Market Sector
CNS
Development Status
Phase II completed, Phase II/III trials suspended
